CTR Coding Break – Coding Radiation Therapy Treatment

Oncology Coding Break

Published/Updated Date: March 25, 2020

[su_youtube url=”https://youtu.be/djj7SIqbn8k”]

The Registry Partners March 2020 CTR Coding Break discusses Radiation. Coding for radiation treatment has changed significantly for cases beginning with a diagnosis date of 01/01/2018 to provide NCDB with a more complete and accurate description of contemporary radiation treatment. The following is a brief description with several examples taken directly from the CTR Guide to Coding Radiation Therapy Treatment v2.0, February 2020. The NCDB clarification for coding I-131 is addressed along with the radiation treatment volume code of 86 Pelvis (NOS, non-visceral). Phase terminology is explained replacing the terms regional and boost. The total dose is further clarified reinforcing doses should only be summed across phases to create a Total dose when all phases were delivered sequentially not simultaneously. Finally, phase dose and total dose are clarified for any treatment modality coded between 07 and 16 which consists of brachytherapy, radioisotopes, and infusion therapy. An explanation is provided when the dose should be coded in cGy or coded to 999998. 

Related

Oncology Coding Break – Surgical Margins of the Primary Site

Oncology Coding Break – Surgical Margins of the Primary Site

https://youtu.be/i76sHRlM_Ec The Surgical Margins of the Primary Site describe the final status of margins following the resection of the primary tumor. This data item is an important quality measure for pathology reporting, contributes to staging, and serves as a...

Oncology Coding Break – Pancreatic Cancer: Surgical Insights

Oncology Coding Break – Pancreatic Cancer: Surgical Insights

https://youtu.be/2PsgJKj3lfw In this session of the Oncology Coding Break, we focus on surgical resections for pancreatic cancer. Anatomy is reviewed to help us be knowledgeable of what may be excised during a pancreatic surgery. The pancreas has 3 main sections...

Stay in Touch

Get our latest articles, registry insights, and company news straight to your inbox.

This field is for validation purposes and should be left unchanged.